Atossa Therapeutics (NASDAQ:ATOS) is acquiring 19.99% of the capital stock of closely-held Dynamic Cell Therapies for $2-million, in addition to $3-million previously paid to Dynamic,
“This investment in Dynamic is an important step in pursuing our strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space,” Steven Quay, M.D., Ph.D., chairman, president and CEO of Atossa, said in a statement.
“We believe that as an active investor in the development of Dynamic we will be well positioned to evaluate future opportunities while strategically managing our cash position,” he added.
